{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+15+mg",
    "query": {
      "intervention": "Rivaroxaban 15 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+15+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T07:36:40.848Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02584660",
      "title": "A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Standard-of-care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2015-10-15",
      "completion_date": "2017-03-22",
      "has_results": true,
      "last_update_posted_date": "2018-06-01",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 50,
      "location_summary": "Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02584660"
    },
    {
      "nct_id": "NCT03702582",
      "title": "Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-04-30",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03702582"
    },
    {
      "nct_id": "NCT01830543",
      "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 15 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 10 mg",
          "type": "DRUG"
        },
        {
          "name": "aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "vitamin K antagonist (VKA)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "prasugrel",
          "type": "DRUG"
        },
        {
          "name": "ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2124,
      "start_date": "2013-05-10",
      "completion_date": "2016-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 86,
      "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830543"
    },
    {
      "nct_id": "NCT00440193",
      "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin followed by VKA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3449,
      "start_date": "2007-03",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440193"
    },
    {
      "nct_id": "NCT02376010",
      "title": "Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 110,
      "start_date": "2015-04-02",
      "completion_date": "2018-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02376010"
    },
    {
      "nct_id": "NCT03968393",
      "title": "Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stroke",
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Non-vitamin K oral anticoagulant (NOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Population Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 2270,
      "start_date": "2019-06-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03968393"
    },
    {
      "nct_id": "NCT03242278",
      "title": "Real-world Dosing Patterns of Rivaroxaban in the United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12507,
      "start_date": "2016-02-12",
      "completion_date": "2016-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03242278"
    },
    {
      "nct_id": "NCT01674647",
      "title": "Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K antagonist (VKA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1504,
      "start_date": "2012-10",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 66,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "East Palo Alto",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674647"
    },
    {
      "nct_id": "NCT06953726",
      "title": "Comparing the Safety and Efficacy of Apixaban and Rivaroxaban",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2026-06-01",
      "completion_date": "2033-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 9,
      "location_summary": "West Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06953726"
    },
    {
      "nct_id": "NCT02313909",
      "title": "Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Acetylsalicylic acid (Aspirin, BAY1019036)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban-Placebo",
          "type": "OTHER"
        },
        {
          "name": "Aspirin-Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7213,
      "start_date": "2014-12-23",
      "completion_date": "2018-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-09-29T07:36:40.848Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Long Beach, California • Stanford, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02313909"
    }
  ]
}